Document Detail

Aspirin and other antiplatelet drugs in the prophylaxis of thrombosis.
MedLine Citation:
PMID:  3332089     Owner:  NLM     Status:  MEDLINE    
Aspirin is of proven value as an antithrombotic drug. In unstable angina it reduces the risk of death and myocardial infarction by half. After a myocardial infarction it reduces the risk of death by about 10% and of coronary incidence (coronary death or definite myocardial infarction) by about 25%. These effects appear to be additive with those of beta-blocking drugs. Aspirin also reduces the risk of occlusion of aortocoronary saphenous vein grafts by about half. In transient cerebral ischaemia, aspirin may reduce the risk of stroke and death by 50%. In most clinical trials to date the daily dose of aspirin ranges from 325 mg to 1400 mg. Interest in very low doses of aspirin (less than 60 mg daily) is considerable but has yet to be translated into proven clinical benefit. Dipyridamole has not been shown to be effective as an antithrombotic when used alone. Its antiplatelet action ex vivo may be enhanced by combination with aspirin but clinical trials have shown relatively little advantage of the combination over aspirin alone. Sulphinpyrazone has not become established as a first line antithrombotic drug. Epoprostenol is useful in extracorporeal circulations to prevent platelet consumption and possibly in severe inoperable peripheral vascular disease.
J Webster; A S Douglas
Related Documents :
2519899 - Aspirin, platelets and prevention of vascular disease.
9341639 - Unstable angina: integrating new treatments.
9779029 - Management of acute coronary syndromes with low molecular weight heparin: timi 11a and ...
16721199 - Which strategy should be used for acute st-elevation myocardial infarction in patients ...
10101569 - A case report of heparin resistance due to acquired antithrombin iii deficiency.
12082199 - Bleeding complications of platelet glycoprotein iib/iiia inhibitor abciximab (reopro ).
1430689 - Intracoronary ultrasound predictors of adverse outcomes after coronary artery intervent...
23076969 - Obstruction in hypertrophic cardiomyopathy: how often does it occur? should it be treat...
7721919 - The use of apache iii to evaluate icu length of stay, resource use, and mortality after...
Publication Detail:
Type:  Clinical Trial; Journal Article; Review    
Journal Detail:
Title:  Blood reviews     Volume:  1     ISSN:  0268-960X     ISO Abbreviation:  Blood Rev.     Publication Date:  1987 Mar 
Date Detail:
Created Date:  1988-11-23     Completed Date:  1988-11-23     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8708558     Medline TA:  Blood Rev     Country:  SCOTLAND    
Other Details:
Languages:  eng     Pagination:  9-20     Citation Subset:  IM    
Department of Medicine and Therapeutics, University of Aberdeen.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aspirin / therapeutic use*
Clinical Trials as Topic
Coronary Disease / prevention & control*
Coronary Thrombosis / prevention & control*
Platelet Aggregation Inhibitors / therapeutic use*
Reg. No./Substance:
0/Platelet Aggregation Inhibitors; 50-78-2/Aspirin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The value of indium-labelled leucocytes in clinical practice.
Next Document:  The role of pentostatin (2'-deoxycoformycin, dCF) in the management of lymphoproliferative malignanc...